A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs IRL 790 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.
- 05 Dec 2017 Status changed from planning to not yet recruiting.
- 27 Nov 2017 New trial record